Viz.ai Named to Forbes 2021 Next Billion-Dollar Startups List and State of AI Report 2021 After Record First Half
SAN FRANCISCO–(BUSINESS WIRE)–#AI–Viz.ai, the world leader in AI-powered intelligent care coordination, has been named to the Forbes 2021 Next Billion-Dollar Startups list. The prestigious list includes the 25 fastest-growing venture-backed startups in 2021 and follows the company’s inclusion in the Forbes AI 50 list for the third consecutive year. Viz.ai was also named in the prestigious State of AI report that highlights companies showing real-world performance breakthroughs in computer vision and biology over the past 12 months.
2021 has seen Viz.ai complete a period of record growth as the company expands product and geographic offerings and marks major milestones in new customer acquisition during the first half of its fiscal year. Viz.ai added three new senior executives during the half as the company continues its expansion beyond stroke to vascular and peripheral vascular indications with the launch of new AI modules for aortic disease and pulmonary embolism (PE) care coordination.
The expanded product line comes on the back of a record six months of growth in the first half of 2021, when Viz.ai exceeded 850 hospitals using its platform to triage stroke patients. Prominent hospitals and health systems including Sentara Healthcare, University of Pittsburgh Medical Center (UPMC) and Thomas Jefferson University Hospital selected the Viz AI-powered care coordination platform to help streamline workflow, deliver better patient outcomes and improve health system economics. The Viz platform leverages AI to alert and activate care teams, provide high-fidelity mobile image viewing, patient information and secure embedded messaging, which enables multidisciplinary teams to make faster treatment decisions for patients. The result increases access to care and improves outcomes for patients. The Viz AI-powered care coordination platform reads one and a half patient scans every minute.
Helping drive further growth, Viz.ai has added key new members to its leadership team, appointing Kelli Castellano as chief marketing officer; Jayme Strauss RN, MSN, MBA, SCRN, as chief clinical officer; and Steve Sweeney as vice president of business development and strategy.
Kelli Castellano is an experienced growth marketing and communications strategist with more than 20 years of experience in business-to-business technology marketing. She joined Viz.ai from TigerConnect, where she helped drive widespread adoption of its clinical collaboration platform.
Jayme Strauss is the former executive director of neurosciences at Piedmont Healthcare, a 16-hospital community health system where she implemented the Viz.ai platform successfully before deciding to join the company as its first chief clinical officer.
Steve Sweeny comes to Viz.ai following a seven-year tenure at Medtronic, where he was vice president of business development and strategy for the company’s neuroscience portfolio.
This news follows several other key milestones Viz.ai has achieved year to date:
- Viz.ai’s record first half began with the company securing $71 million in Series C funding and announcing plans to expand beyond stroke and in geographies outside the U.S.
- In the next quarter, the company expanded to Europe with a CE mark and extended distribution partnership.
- In July, the company announced a partnership with Avicenna.AI, paving the way for faster clinical decision making and care for patients suffering from PE and aortic disease.
- In another landmark ruling, Viz.ai received a New Technology Add-on Payment (NTAP) renewal from Centers for Medicare & Medicaid Services (CMS) for its AI-powered stroke triage module, Viz LVO (formerly known as Viz ContaCT). The reimbursement opportunity will continue to give more patients access to life-changing stroke technology, which has demonstrated significant improvements to patient outcomes through FY 2022. Viz LVO is eligible for reimbursement up to $1,040 per eligible patient.
“We are proud to be named to the Forbes Next Billion-Dollar Startups list, which reflects Viz.ai’s exceptional growth potential as a result of thoughtful expansion and our demonstrated ability to scale,” said Dr Chris Mansi, co-founder and CEO of Viz.ai. “Recently, we’ve seen significant growth as we continue to expand our intelligent care coordination platform beyond stroke and internationally, showcasing the power of the Viz platform to streamline workflow, improve patient outcomes and improve economics across the entire health system.”
About Viz.ai, Inc.
Viz.ai is the leader in AI-driven intelligent care coordination. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging.
Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Greenoaks, CRV, Threshold Ventures, Innovation Endeavors, Susa Ventures, Scale Venture Partners and Insight Partners.
Pazanga Health Communications